News

Amentum Holdings Sees Significant Stock Gains This Week

Amentum Holdings Sees Significant Stock Gains This Week

Amentum Holdings Stock Rises Significantly

Amentum Holdings, Inc. (NYSE: AMTM) has made headlines recently as shares experienced a remarkable increase on a Tuesday following a strong earnings report released the day prior. The company's adjusted earnings per share for the fourth quarter were reported at 63 cents, exceeding analysts' expectations, which had set the consensus estimate at 59 cents. Additionally, Amentum's quarterly revenue reached an impressive $3.925 billion, reflecting a year-over-year growth of 77%, surpassing the expected figure of $3.613 billion.

Revenue Growth and Performance Metrics

In terms of pro forma revenues, which incorporate results prepared in accordance with the requirements of Article 11 of Regulation S-X, Amentum noted a 10% increase for the fourth quarter. The success was particularly notable in their Digital Solutions segment, which saw an 11% rise in revenue, while Global Engineering Solutions reported a 9% increase. This growth underscores the company’s strong market position and adaptability in the competitive defense sector.

Profitability and Cash Flow Insights

Examining profitability, Amentum's operating income dramatically surged by 400%, amounting to $135 million. Adjusted EBITDA also saw a growth of 8%, reaching $300 million, even though the adjusted EBITDA margin saw a slight decline of 10 basis points to 7.7%. For the quarter ending recently, Amentum generated a net cash flow of $270 million from operating activities, which illustrates strong operational efficiency despite cash outflow in investing and financing activities totaling $8 million and $559 million respectively.

Backlog and Bookings Performance

In another positive sign for Amentum Holdings, the total backlog climbed to $47.1 billion, up from $45.0 billion year-over-year, representing a 5% increase. This growth was supported by $16.5 billion in net bookings and a solid book-to-bill ratio of 1.2x. It’s worth noting that the funded backlog as of the recent quarter stood at $5.6 billion, indicating a robust pipeline of upcoming projects set to drive future growth.

Key Defense Contract Win

Earlier this month, Amentum was selected for the Remotely Piloted Aircraft (RPA) Maintenance Support IDIQ contract by the Air Force Air Combat Command. This contract, with a ceiling value of up to $995 million, highlights Amentum's growing presence in the defense sector. The MQ-9 Reaper, a crucial unmanned aerial system, represents a leap in military capability, with advanced technologies that ensure that the U.S. maintains a competitive edge in modern warfare.

Future Outlook for Amentum Holdings

Amentum Holdings has provided guidance for 2026, projecting revenues to fall between $13.95 billion and $14.30 billion. This forecast aligns quite closely with the analysts' consensus estimate of $14.08 billion, reflecting confidence in the company's strategic direction. As AMTM shares continue to respond positively to the announcements, they were reported to be trading higher by 22.7% to $31.13 in recent trading activity.

Frequently Asked Questions

What were Amentum Holdings' fourth-quarter earnings?

The company reported adjusted earnings of 63 cents per share, exceeding analyst expectations of 59 cents.

How much did Amentum's revenue grow in the fourth quarter?

Amentum posted a revenue of $3.925 billion, showing a significant year-over-year increase of 77%.

What is Amentum Holdings' current backlog?

The total backlog is reported at $47.1 billion, reflecting a 5% increase from the previous year.

What major contract did Amentum secure recently?

The company was awarded a $995 million RPA Maintenance Support IDIQ contract by the Air Force Air Combat Command.

What is the revenue outlook for 2026?

Amentum expects to generate between $13.95 billion and $14.30 billion in 2026, aligning closely with analysts' estimates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

NanoXplore Gains Government Support for Innovative Battery Tech

Updated Category News Views 193

NanoXplore Secures Government Funding for Battery Innovation In a significant development for the battery technology sector, NanoXplore Inc. (TSX: GRA and OTCQX: NNXPF), a frontrunner in graphene production, recently announced a contribution of up to $2.75 million from the Canadian government as part of the Energy Innovation Program (EIP). This contribution is expected to...

Continue Reading
Equinor ASA Declares Cash Dividend for First Quarter 2025

Updated Category News Views 272

Equinor ASA Announces an Exciting Cash Dividend Equinor ASA (OSE: EQNR, NYSE: EQNR) has made an important announcement regarding its dividend strategy for shareholders. As part of its ongoing commitment to deliver value, the company has declared a cash dividend of NOK 3.7740 per share for the first quarter of 2025. Understanding the Dividend Amount The cash dividend of...

Continue Reading
RIAS A/S Shares Insights from Recent Half-Year Performance

Updated Category News Views 469

Analyzing the Half-Year Performance of RIAS A/S RIAS A/S has recently released its half-year report, offering a clear view into the company's operational status and financial health. This report is crucial for stakeholders and potential investors to understand how RIAS A/S is navigating through the current economic landscape. Key Financial Highlights In this reporting...

Continue Reading
Starbucks Stock Analysis: Opportunities and Challenges Ahead

Updated Category News Views 156

Understanding Starbucks Stock Performance Starbucks Corporation's stock, trading under the ticker SBUX, is currently observed at a forward 12-month Price/Earnings ratio of 24.79x. This figure places it just slightly below the Zacks Restaurant industry average of 24.97x. However, it's noteworthy that SBUX's valuation exceeds the broader Retail-Wholesale sector, which has a...

Continue Reading
Explore Innovations at the 2024 GenScript Biotech Forum

Updated Category News Views 314

Join Experts at the 2024 GenScript Biotech Global Forum The year ahead is shaping up to be crucial for Cell and Gene Therapy (CGT), and the "2024 GenScript Biotech Global Forum" offers an ideal setting for essential discussions. Top experts will gather to exchange insights on groundbreaking therapies such as Amtagvi and PM359, which promise new opportunities in treatment....

Continue Reading